Efficacy and Safety of PD-1 Inhibitor SHR-1210 With Chemoradiotherapy in Locally Advanced Cholangiocarcinoma

被引：0
|
作者：
Yue, J. [1 ,2 ]
Feng, R. [1 ,2 ]
机构：
[1] Shandong First Med Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Shandong Acad Med Sci, Jinan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2125
引用
收藏
页码：E85 / E85
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of PD-1 Antibody SHR-1210 Combined with Concurrent Chemoradiotherapy to Treat Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase Ib Clinical Trial
    Pang, Q.
    Zhang, W.
    Zhao, J.
    Zhang, T.
    Zhang, Q.
    Chen, X.
    Zhao, L.
    Wang, J.
    Yuan, Z.
    Wang, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S46 - S46
  • [2] Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
    Huang, Jing
    Xu, Binghe
    Mo, Hongnan
    Zhang, Weilong
    Chen, Xuelian
    Wu, Dawei
    Qu, Dong
    Wang, Xingyuan
    Lan, Bo
    Yang, Beibei
    Wang, Pei
    Zhang, Hongtu
    Yang, Qing
    Jiao, Yuchen
    CLINICAL CANCER RESEARCH, 2018, 24 (06) : 1296 - 1304
  • [3] Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild-type EGFR and ALK.
    Zhou, Caicun
    Gao, Guanghui
    Wang, Yi Na
    Zhao, Jun
    Chen, Gongyan
    Liu, Zhihua
    Gu, Kangsheng
    Huang, Meijuan
    He, Jianxing
    Chen, Jianhua
    Ma, Zhiyong
    Feng, Ji Feng
    Shi, Jianhua
    Wang, Quanren
    Yang, Ying
    Yu, Xinmin
    Cheng, Ying
    Yao, Yu
    Ren, Shengxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer.
    Liu, Jieqiong
    Jiang, Zefei
    Li, Qian
    Li, Ying
    Liu, Qiang
    Song, Erwei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation
    Gao, G.
    Wang, Y.
    Ren, S.
    Liu, Z.
    Chen, G.
    Gu, K.
    Zang, A.
    Zhao, J.
    Guo, R.
    He, J.
    Lin, X.
    Pan, Y.
    Ma, Z.
    Wang, Z.
    Fan, M.
    Liu, Y.
    Cang, S.
    Yang, X.
    Wang, Q.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S654 - S654
  • [6] The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma
    Shen, Dijian
    Chen, Qixun
    Wu, Jie
    Li, Jianqiang
    Tao, Kaiyi
    Jiang, Youhua
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (01) : 1 - 10
  • [7] Efficacy and safety of PD-1 inhibitor combined with anlotinib in the treatment of advanced
    Song, L.
    Yu, X.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 145 - 145
  • [8] The efficacy and safety of neoadjuvant treatment with the PD-1 inhibitor for locally advanced colorectal cancer: a meta-analysis
    Yu, Yan
    Huang, Lin
    Yan, Rong
    Jiang, Min
    Li, Shuang-Jiao
    Fan, Wang-Dong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer
    Wang, Cong
    Liu, Lijun
    Li, Xia
    Lei, Jia
    Li, Yiqian
    Shen, Zhibo
    Shi, Huirong
    Cheng, Yan
    FUTURE ONCOLOGY, 2024, 20 (20) : 1415 - 1426
  • [10] Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
    Wang, J.
    Zhang, Z.
    Zhang, F.
    Song, Q.
    Zhang, L.
    Liu, Z.
    Ma, J.
    Yan, X.
    Wang, L.
    Tao, H.
    Zhang, S.
    Li, X.
    Zhi, X.
    Hu, Y.
    Jiao, S.
    ANNALS OF ONCOLOGY, 2019, 30
12345